A gut response: Modulating chemotherapy efficacy with microbial metabolites

Kylynda C Bauer; Tim F Greten

doi:10.1016/j.immuni.2023.03.011

A gut response: Modulating chemotherapy efficacy with microbial metabolites

Immunity. 2023 Apr 11;56(4):750-752. doi: 10.1016/j.immuni.2023.03.011.

Authors

Kylynda C Bauer¹, Tim F Greten²

Affiliations

¹ Gastrointestinal Malignancy Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
² Gastrointestinal Malignancy Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; NCI CCR Liver Cancer Program, National Institutes of Health, Bethesda, MD, USA. Electronic address: tim.greten@nih.gov.

PMID: 37044066
DOI: 10.1016/j.immuni.2023.03.011

Abstract

Despite clinical advances, chemotherapy largely fails in metastatic cancers. Commensal bacteria can indicate chemotherapy efficacy. In a recent issue of Nature, Tintelnot et al.¹ demonstrate that bacterial metabolite 3-IAA amplifies chemotherapy outcomes via autophagy pathways in metastatic pancreatic ductal adenocarcinoma.

Published by Elsevier Inc.

Publication types

Comment

MeSH terms

Adenocarcinoma*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma, Pancreatic Ductal* / drug therapy
Carcinoma, Pancreatic Ductal* / pathology
Humans
Pancreatic Neoplasms* / drug therapy
Pancreatic Neoplasms* / pathology